EA201070609A1 - Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств - Google Patents

Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств

Info

Publication number
EA201070609A1
EA201070609A1 EA201070609A EA201070609A EA201070609A1 EA 201070609 A1 EA201070609 A1 EA 201070609A1 EA 201070609 A EA201070609 A EA 201070609A EA 201070609 A EA201070609 A EA 201070609A EA 201070609 A1 EA201070609 A1 EA 201070609A1
Authority
EA
Eurasian Patent Office
Prior art keywords
obesity
methods
disorders
diseases
treating
Prior art date
Application number
EA201070609A
Other languages
English (en)
Inventor
Джонатан Дэвид Рот
Ален Д. Бэрон
Кристен Андерсон
Original Assignee
Амилин Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амилин Фармасьютикалз, Инк. filed Critical Амилин Фармасьютикалз, Инк.
Publication of EA201070609A1 publication Critical patent/EA201070609A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Раскрыты способы лечения ожирения или ассоциированных с ожирением расстройств. Эти способы включают применение агентов против ожирения, направленных на передний мозг, в комбинации с агентами против ожирения, направленными на задний мозг.
EA201070609A 2007-11-14 2007-11-14 Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств EA201070609A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/084733 WO2009064298A1 (en) 2007-11-14 2007-11-14 Methods for treating obesity and obesity related diseases and disorders

Publications (1)

Publication Number Publication Date
EA201070609A1 true EA201070609A1 (ru) 2010-12-30

Family

ID=39642692

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070609A EA201070609A1 (ru) 2007-11-14 2007-11-14 Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств

Country Status (16)

Country Link
US (1) US20100323955A1 (ru)
EP (1) EP2219664A1 (ru)
JP (1) JP2011503180A (ru)
KR (1) KR20100098628A (ru)
CN (1) CN101939022A (ru)
AU (1) AU2007360979B2 (ru)
BR (1) BRPI0722276A2 (ru)
CA (1) CA2705708A1 (ru)
EA (1) EA201070609A1 (ru)
IL (1) IL205730A0 (ru)
MA (1) MA31842B1 (ru)
MX (1) MX2010005345A (ru)
TN (1) TN2010000214A1 (ru)
UA (1) UA97707C2 (ru)
WO (1) WO2009064298A1 (ru)
ZA (1) ZA201003497B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2813038C (en) * 2010-09-28 2021-12-28 Amylin Pharmaceuticals, Llc Highly soluble leptins
US20140221282A1 (en) * 2011-05-25 2014-08-07 Astrazeneca Pharmaceuticals Lp Long duration dual hormone conjugates
WO2013009539A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
CA2861392C (en) 2012-01-26 2021-08-17 Christopher J. Soares Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
CN104822374A (zh) * 2012-09-27 2015-08-05 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
WO2015017455A1 (en) * 2013-07-30 2015-02-05 Soares Christopher J Cgrp agonist peptides
US11180538B2 (en) * 2015-11-13 2021-11-23 University Of Utah Research Foundation Combinatorial gene construct and non-viral delivery for anti-obesity
IL265099B2 (en) 2016-09-02 2024-09-01 Christopher J Soares Medicinal compositions containing an effective amount of a calcitonin gene-related peptide (CGRP) receptor antagonist, or a pharmaceutically acceptable salt thereof, for the treatment of glaucoma
RS64850B1 (sr) 2016-09-12 2023-12-29 Amryt Pharmaceuticals Inc Metodi za detektovanje neutrališućih antitela na leptin
CN106749524B (zh) * 2016-12-05 2020-08-18 华南理工大学 一种抗肥胖七肽npvwkrk
SG11202000940XA (en) 2017-08-24 2020-02-27 Novo Nordisk As Glp-1 compositions and uses thereof
WO2021094259A1 (en) 2019-11-11 2021-05-20 Boehringer Ingelheim International Gmbh Npy2 receptor agonists
KR20220143036A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 약학적 제형
WO2022029231A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists
EP4091625A1 (en) * 2021-05-22 2022-11-23 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
WO2022248419A2 (en) * 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914250A (en) * 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
US5081122A (en) * 1990-03-05 1992-01-14 Sterling Drug Inc. Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof
US5013837A (en) * 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
US4973587A (en) * 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5292736A (en) * 1993-02-26 1994-03-08 Sterling Winthrop Inc. Morpholinoalkylindenes as antiglaucoma agents
US5625032A (en) * 1993-07-21 1997-04-29 Amylin Pharmaceuticals, Inc. Selective amylin antagonist peptides and uses therefor
RU2177331C2 (ru) * 1993-09-07 2001-12-27 Амилин Фармасьютикалз, Инк. Способы регулирования моторики желудочно-кишечного тракта
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US5856098A (en) * 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US5552524A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) * 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5532237A (en) * 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
EP0887340A4 (en) * 1996-02-06 2000-03-29 Japan Tobacco Inc CHEMICAL COMPOUNDS AND THEIR PHARMACEUTICAL USE
US6007998A (en) * 1996-04-22 1999-12-28 Merck & Co., Inc. Leptin assay
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
CN1230966A (zh) * 1996-09-20 1999-10-06 赫彻斯特股份公司 勒帕素拮抗剂在用于治疗ii型糖尿病胰岛素耐受性中的用途
EP0945440B1 (en) * 1996-12-16 2004-05-26 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
DK1629849T4 (en) * 1997-01-07 2017-12-04 Amylin Pharmaceuticals Llc Pharmaceutical compositions comprising exedins and agonists thereof
US6410511B2 (en) * 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
HU228509B1 (en) * 1997-02-21 2013-03-28 Bayer Ip Gmbh Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
WO1998047505A1 (fr) * 1997-04-23 1998-10-29 Banyu Pharmaceutical Co., Ltd. Antagoniste de recepteur de neuropeptide y
US6001836A (en) * 1997-05-28 1999-12-14 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: cyanoguanidine derivatives
EP1076644B1 (en) * 1998-04-29 2004-06-23 Ortho-McNeil Pharmaceutical, Inc. N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
US6329395B1 (en) * 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
DE19837627A1 (de) * 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
HN1998000027A (es) * 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
WO2000025806A1 (en) * 1998-11-04 2000-05-11 Aronne Louis J Method for weight control
US6191160B1 (en) * 1998-11-10 2001-02-20 Merck & Co., Inc. Spiro-indolines as Y5 receptor antagonists
ES2161594B1 (es) * 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
US6365633B1 (en) * 1999-03-19 2002-04-02 Knoll Pharmaceutical Company Method of treating eating disorders
FR2792314B1 (fr) * 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6124331A (en) * 1999-06-30 2000-09-26 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US6340683B1 (en) * 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
US6214853B1 (en) * 1999-06-30 2001-04-10 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
TWI279402B (en) * 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
DE19949319A1 (de) * 1999-10-13 2001-06-13 Ruetgers Vft Ag Verfahren zur Herstellung von Arylalkylethern
DE60109756T2 (de) * 2000-02-22 2005-08-25 Banyu Pharmaceutical Co., Ltd. Imidazolin-verbindungen
US6930185B2 (en) * 2000-04-28 2005-08-16 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
CA2408913A1 (en) * 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
AU2002253838B2 (en) * 2000-10-30 2006-11-09 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising anti-diabetic and anticonvulsant agents
GB0105069D0 (en) * 2001-03-01 2001-04-18 Univ Ulster The Modified peptide
EP1494704A1 (en) * 2002-04-04 2005-01-12 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
JP2005533849A (ja) * 2002-07-18 2005-11-10 メルク　エンド　カムパニー　インコーポレーテッド 肥満治療のための組み合わせ療法
US7141561B2 (en) * 2002-07-25 2006-11-28 Sanofi-Aventis Deutschland Gmbh Substituted diaryl heterocycles, process for their preparation and their use as medicaments
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
WO2005033137A1 (en) * 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Modified ciliary neurotrophic factor polypeptides with reduced antigenicity
US20070149451A1 (en) * 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
ATE360631T1 (de) * 2003-12-19 2007-05-15 Bristol Myers Squibb Co Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
EP2286838A3 (en) * 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
EP1954313A1 (en) * 2005-11-01 2008-08-13 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
WO2007055743A2 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders

Also Published As

Publication number Publication date
CN101939022A (zh) 2011-01-05
MX2010005345A (es) 2010-08-31
AU2007360979B2 (en) 2014-04-10
MA31842B1 (fr) 2010-11-01
AU2007360979A1 (en) 2009-05-22
EP2219664A1 (en) 2010-08-25
UA97707C2 (ru) 2012-03-12
JP2011503180A (ja) 2011-01-27
WO2009064298A1 (en) 2009-05-22
IL205730A0 (en) 2010-11-30
BRPI0722276A2 (pt) 2014-04-22
AU2007360979A2 (en) 2010-07-15
TN2010000214A1 (en) 2011-11-11
CA2705708A1 (en) 2009-05-22
ZA201003497B (en) 2011-02-23
KR20100098628A (ko) 2010-09-08
US20100323955A1 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
EA201070609A1 (ru) Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств
DK1814590T4 (da) Behandling af obesitet og beslægtede sygdomme.
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
EA201370208A1 (ru) Формы рифаксимина и их применение
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
MX2020009403A (es) Compuestos con actividad anticancer.
SI2254869T1 (sl) Novi 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji CX3CR1 in p40
ATE476418T1 (de) Benzamidderivate und assoziierte verwendungen
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
IL207277A0 (en) Novel 1 - benzyl - 3 - hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp - 1, cx3cr1 and p40
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
WO2007055743A3 (en) Treatment of obesity and related disorders
EA201070637A1 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н
EA201000433A1 (ru) Лечение вазомоторных симптомов
EA201000864A1 (ru) Фенилоксетанильные производные
CY1121275T1 (el) Θεραπεια των διαταραχων του εθισμου και του ελεγχου της παρορμητικοτητας χρησιμοποιωντας αναστολεις pde7
ECSP10010250A (es) Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad